Elos Interim Report, 1 January–31 March 2015

Regulatory News:

Elos (STO:ELOSB)

· 23 April marked the conclusion of the acquisition of the North American company, Onyx Medical LLC, based in Memphis, TN, US. The company is a leading supplier to the Trauma & Extremities segment in the Orthopaedics area.

· Net sales increased and totalled SEK 105.5 M (88.5), a rise of 11.7%*. Order bookings amounted to SEK 96.1 M (115.4), down 21.6%*.

· Operating profit totalled SEK 5.7 M (6.3). Earnings for the quarter were adversely affected by non-recurring expenses of SEK 4.5 M (0). Adjusted for these items, operating profit amounted to SEK 10.2 M, with the year-on-year improvement mainly due to a positive volume trend.

· Profit after net financial items totalled SEK 7.6 M (4.3). Net financial items were positively impacted by exchange-rate gains of SEK 2.9 M (losses: 0.5).

· Profit after tax for continuing operations amounted to SEK 5.6 M (3.2), corresponding to SEK 0.93 (0.53) per share. · Cash flow after investments totalled SEK 6.2 M (3.0).

* Adjusted for exchange-rate fluctuations during the year.

President and CEO, Johannes Lind-Widestam, comments:

”During the first quarter, we were able to transform the robust order bookings during 2014 into deliveries. Sales rose 11.7%, adjusted for exchange-rate differences. The underlying operating profit, adjusted for non-recurring items, amounted to SEK 10.2 M and has continued to move in a positive direction, with a year-on-year improvement of some 60%. Order bookings for the quarter were lower than in the year-earlier period. The decline was due to a combination of intense order bookings during Q1-2014, plus a reduction in lead times to customers. Customers place orders for delivery with shorter lead times. The underlying order trend remains positive.

The acquisition of Onyx provides a platform in the North American market, which we have aimed at, and will significantly raise our market share in the Trauma and Spine area. The acquisition will have a directly positive impact on the Group’s earnings per share on an annual basis, as well as on other key data.”

The information in this interim report is such that Elos AB (publ) is obligated to publish in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was issued for publication on 27 April 2015 at 13:00 a.m. (CET)

For additional information about the Elos Group, visit www.elos.se

This information was brought to you by Cision http://news.cision.com